|
Hormone refractory prostate cancer
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CRPC cells showed an increased expression of ACSL3 and an expression pattern of AKR1C3 and UGT2B similar to ACSL3-overexpressing cells.
|
28771887 |
2017 |
|
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma Huh7 cells.
|
18003621 |
2008 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma Huh7 cells.
|
18003621 |
2008 |
|
Malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Very long-chain acyl-CoA synthetase 3: overexpression and growth dependence in lung cancer.
|
23936004 |
2013 |
|
Carcinoma of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Very long-chain acyl-CoA synthetase 3: overexpression and growth dependence in lung cancer.
|
23936004 |
2013 |
|
Primary malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Very long-chain acyl-CoA synthetase 3: overexpression and growth dependence in lung cancer.
|
23936004 |
2013 |
|
Hormone sensitive prostate cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A public database showed that ACSL3 level was higher in CRPC than in hormone-sensitive prostate cancer.
|
28771887 |
2017 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Among the five family isoforms, ACSL1 and ACSL4 are able to promote ungoverned cell growth, facilitate tumor invasion and evade programmed cell death, while ACSL3 may have relatively complex functions in different types of cancer.
|
30008815 |
2018 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Among the five family isoforms, ACSL1 and ACSL4 are able to promote ungoverned cell growth, facilitate tumor invasion and evade programmed cell death, while ACSL3 may have relatively complex functions in different types of cancer.
|
30008815 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Among the five family isoforms, ACSL1 and ACSL4 are able to promote ungoverned cell growth, facilitate tumor invasion and evade programmed cell death, while ACSL3 may have relatively complex functions in different types of cancer.
|
30008815 |
2018 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Elevated expression of liver X receptor alpha (LXRα) in myocardium of streptozotocin-induced diabetic rats.
|
21136146 |
2011 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ENDOD1 and ACSL3 showed down-regulation in high-grade and metastatic PCa, while MCCC2 was overexpressed in low-grade PCa.
|
21829708 |
2011 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ENDOD1 and ACSL3 showed down-regulation in high-grade and metastatic PCa, while MCCC2 was overexpressed in low-grade PCa.
|
21829708 |
2011 |
|
Malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, ACSL3 is essential for mutant KRAS lung cancer tumorigenesis in vivo and is highly expressed in human lung cancer.
|
27477280 |
2016 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, ACSL3 is essential for mutant KRAS lung cancer tumorigenesis in vivo and is highly expressed in human lung cancer.
|
27477280 |
2016 |
|
Primary malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, ACSL3 is essential for mutant KRAS lung cancer tumorigenesis in vivo and is highly expressed in human lung cancer.
|
27477280 |
2016 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
Furthermore, we examined the role of ACSL3 in the androgen metabolism of prostate cancer.
|
28771887 |
2017 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Furthermore, we examined the role of ACSL3 in the androgen metabolism of prostate cancer.
|
28771887 |
2017 |
|
ovarian neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
|
Malignant neoplasm of ovary
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
|
Hormone refractory prostate cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
Interestingly, microarray analysis revealed that OCT1 regulates CRPC-specific target genes in addition to representative AR-regulated genes such as ACSL3.
|
30649323 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Moreover, a major target of AR/Oct1 complex, acyl-CoA synthetase 3 (ACSL3), contributes to tumor growth in nude mice, and its high expression is associated with poor prognosis in prostate cancer patients.
|
27270436 |
2016 |